Assessing the validity, responsiveness and reliability of the Recap measure of eczema control

Bhanot, Alisha; Peters, Tim J.; Ridd, Matthew J

doi:10.1111/bjd.19709

Cited by 11 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were also no floor or ceiling effects for the overall total RECAP scores. These findings were consistent with the development and initial testing of the RECAP instrument as well as other validation studies in Europe, with 1 study including patients from the outpatient dermatology department in Bristol, UK ( 19 – 22 , 28 , 29 ). Our study demonstrated strong correlations of RECAP with other eczema outcome measures.…”

Section: Discussionsupporting

confidence: 88%

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Yew,

Phuan,

Zhao

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

Recap of atopic eczema (RECAP) is a self-reported 7-item questionnaire recommended by the Harmonising Outcome Measures in Eczema initiative to measure eczema control. As RECAP has not been validated in a real-world clinical population in Asia, RECAP was investigated as a measure of eczema control in Singapore. Patients with atopic eczema at the National Skin Centre from July 2019 to January 2020 were included for analysis. Both patient- and physician-reported outcome measures were available for correlation analyses. Correlation analysis was also performed to investigate construct validity, and floor or ceiling effects of RECAP. A total of 260 atopic eczema patients aged between 15 and 87 years were recruited. There were minimal floor and ceiling effects for RECAP scores. There were strong, significant correlations of RECAP with POEM (r = 0.84, p < 0.001) and DLQI (r = 0.81, p < 0.001). Correlation with SCORAD was moderate (r = 0.60, p < 0.001). Correlations remained similar after age, gender, and ethnicity adjustments. Discriminative validity was demonstrated by a significant linear trend of increasing RECAP scores with increasing eczema severity. RECAP demonstrates good discriminative and construct validity evidenced by strong correlations with symptoms and quality of life and moderate correlations with eczema signs. RECAP is useful to measure eczema control in Singapore.

show abstract

Section: Discussionsupporting

confidence: 88%

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Yew,

Phuan,

Zhao

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…In an online survey of 382 participants, RECAP was found to have good validity and reliability. 3 However, the validity and reliability of questionnaires can vary by both population and setting. We investigated the acceptability and validity of RECAP in a clinic setting in Bristol, England.…”

mentioning

confidence: 99%

Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics

Bhanot

Vincent

Peters

et al. 2021

Clin Experimental Derm

Self Cite

View full text Add to dashboard Cite

“…One additional instrument was identified from the 106 responses received from the survey of HOME members. We obtained 58 full texts and identified 12 eligible papers reporting on seven instruments 3,13‐23 (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Measurement properties of patient‐reported outcome measures for eczema control: a systematic review

Stuart

Howells

Pattinson

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Atopic eczema (herein referred to as 'eczema') is a skin disease characterized by remitting and relapsing symptoms. The Harmonising Outcome Measures for Eczema (HOME) initiative was developed to establish a core outcome set (COS) for eczema to be measured for all future eczema trials. The core outcome set for atopic eczema clinical trials includes the domain for patient-reported eczema control, but a review of the validation of available eczema control instruments was lacking. We aimed to review the literature and systematically assess the measurement properties of validated patientreported outcome instruments that capture eczema control. PubMed and Ovid EMBASE were searched up to 24 January 2020 for any study that reported on PROM instrument development or validation. The COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria were used to assess the quality of eligible studies.We screened 12 036 titles and abstracts and 58 full texts. A total of 12 papers were included, reporting on seven PROMS. These were assessed with respect to development, reliability, construct validity and responsiveness. Two instruments, Recap of Atopic Eczema (RECAP) and the Atopic Dermatitis Control Tool (ADCT), have been developed and validated to a sufficient standard to support their recommendation as patient-reported outcome instruments for measuring control of atopic eczema as part of the HOME Core Outcome Set.

show abstract

Assessing the validity, responsiveness and reliability of the Recap measure of eczema control

Cited by 11 publications

References 4 publications

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics

Measurement properties of patient‐reported outcome measures for eczema control: a systematic review

Contact Info

Product

Resources

About